Effect of soy-milk consumption on inflammatory factors, cardiovascular factors ,renal factors, fibrinolytic indice and oxidative stress

Comparison of soy-milk and cow milk consumption on inflammatory factors, cardiovascular factors ,renal factors, fibrinolytic indice and oxidative stress among type-2 diabetic patients with nephropathy stage 1 and 2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105282839N2

Enrollment

Registered

2011-09-06

Start date

2010-09-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Glomerular disorders in diabetes mellitus

Interventions

Intervention 1: In this randomized crossover design, for 4 weeks ? one group consumption cows milk one glass every day . Intervention 2: Other group consumptin cow milk 1 glass every day for 4 weeks.

In this randomized crossover design, for 4 weeks ? one group consumption cows milk one glass every day .

Other group consumptin cow milk 1 glass every day for 4 weeks

Eligibility

Sex/Gender

All

Age

28 Years to 81 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included adults with (>18y old) diagnosis of type 2 diabetics nephropathy (diabetics subjects that had proteinuria more than 300 mg/day and had GFR more than 90 mL/min ); Not having allergy to soy product or caw’s milk. exclusion criteria included diabetic nephropathy patients that they were pregnant or lactation women; changing dosage of oral hypoglycemic agents or lipid-lowering medications; alcohol and cigarette consumption;allergy or intolerance to soybeans or milk ;presence of breast malignant and Not following the research protocol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Soymilk. Timepoint: at baseline and 4,6,10 weeks. Method of measurement: dietary record.	—

Secondary

Measure	Time frame
HbA1c. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Creatinin. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Total cholesterol. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Insulin. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Systolic blood pressure. Timepoint: at 1,4,6,10 weeks. Method of measurement: Blood Pressure Monitor.;Diastolic blood pressure. Timepoint: at 1,4,6,10 weeks. Method of measurement: Blood Pressure Monitor.;Malondialdehyde. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Fibrinogen. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Urine creatinine. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Urine protein. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;BUN. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;TNF-a. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;IL6. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;FBS. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;TG. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Hs-CRP. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;D-dimer. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;HDL. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;LDL. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.	—

Measure

Time frame

HbA1c. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Creatinin. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Total cholesterol. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Insulin. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Systolic blood pressure. Timepoint: at 1,4,6,10 weeks. Method of measurement: Blood Pressure Monitor.;Diastolic blood pressure. Timepoint: at 1,4,6,10 weeks. Method of measurement: Blood Pressure Monitor.;Malondialdehyde. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Fibrinogen. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Urine creatinine. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Urine protein. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;BUN. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;TNF-a. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;IL6. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;FBS. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;TG. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;Hs-CRP. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;D-dimer. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;HDL. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.;LDL. Timepoint: at 1,4,6,10 weeks. Method of measurement: biochemical analysis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Leila Azadbakht

Isfahan University of Medical Sciences

Azadbakht@hlth.mui.ac.ir+98 31 1792 2719

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026